DoMore Diagnostics
Company Overview
DoMore Diagnostics was established to develop novel precision medicine methods to personalize treatment for cancer patients. Their work is based on prominent research from Oslo University Hospital, Oxford University, and University College London. The company aims to use artificial intelligence technology in digital pathology to reduce over- and undertreatment of cancer, overcoming the lack of objective and precise methods for cancer prognosis that limit optimal treatment worldwide.
Mission
DoMore Diagnostics' mission is to bring AI-powered digital biomarkers closer to clinicians and patients, enabling personalized cancer treatment to improve patient outcomes and reduce healthcare costs.
Management
- Torbjørn Furuseth, MD - Chief Executive Officer (CEO) & Co-founder. Experienced in life sciences, radiology, sports medicine, management consulting at McKinsey, and leadership roles in pharma and biotech.
- Sepp De Raedt, PhD - Chief Technology Officer (CTO) & Co-founder. Expert in machine learning methods for diagnostics and prognostics in radiology and pathology, core developer of DoMore Diagnostics' technology.
- Elisabeth M.J. Klaussen, MSc - Head of Quality and Regulatory. Broad experience in Quality Assurance in pharma, biotech, and medtech.
- Andreas Berg Storsve, PhD - VP Operations. Background in life sciences science and business, R&D, business development, and intellectual property.
- Lao Saal, MD, PhD - Medical Director. Cancer scientist and entrepreneur advancing cancer research and precision medicine, founder of SAGA Diagnostics AB, consultant in diagnostics and oncology.
Board of Directors
- Tomas Nordheim Alme, MD - Chairman. Pediatrician with experience in healthcare project and company management, cloud EHR systems, and strategic management education.
- Øyvind Grotmol, MSc - Director. Serial tech entrepreneur and founder of Exabel, investor and advisor in life sciences.
- Yngve Tvedt, MBA - Director. Founder and Chief Investment Officer of Norselab, impact investment platform and investor in Norwegian tech companies.
- Knut Liestøl, Prof - Director. Professor and former department head at University of Oslo with expertise in statistics, mathematical modeling, and deep learning for cancer medical decision support.
- Ketil F. Widerberg, MBA - Director. Experienced in life science and software industries, managing director for Oslo Cancer Cluster, with biotech and software background.
Scientific Advisory Board
- Dr. John L. Marshall, MD - Oncology CMO for Indivumed. Expert in drug development for GI cancer and precision medicine.
- Dr. Jeanine Roodhart, MD, PhD - Medical oncologist and associate professor specialized in colorectal cancer clinical and translational research.
- Dr. Takayuki Yoshino, MD - Deputy Director, National Cancer Center Hospital East, expert in colorectal cancer and multiple professional oncology roles.
- Dr. Frank A. Sinicrope, MD, FACP - Professor at Mayo Clinic, expert in gastrointestinal oncology and colorectal cancer research.
- Prof. Marc Peeters, MD - CEO and Professor at Antwerp University Hospital, with expertise in oncology and colorectal cancer research.
- Prof. Marco Novelli, MD - Professor at University College London, expert in gastrointestinal pathology and colorectal cancer research.
- Prof. Hans-Joachim Schmoll, MD - Leader of clinical oncology research at University Hospital of Halle, Germany, expert in GI oncology.